Study targets virus linked to birth defects
University of Edinburgh College of Medicine News May 16, 2017
Scientists have discovered a key molecule linked to human cytomegalovirus (HCMV) infection, which is harmless for healthy people but can cause miscarriage and birth defects during pregnancy.
Tests on infected cells found that blocking the molecule with a chemical inhibitor stops the virus from multiplying. Dr Finn Grey, a Senior Research Fellow at the University of EdinburghÂs Roslin Institute, said: ÂBy gaining a better understanding of how the virus works, we can develop improved antiviral drugs. While more work is required, this study shows the potential of such approaches.Â
The molecule  called VCP  is a component of the infected cell rather than a substance produced by the virus itself. Researchers at the University of EdinburghÂs Roslin Institute found the virus is dependent on VCP to replicate its genetic material and multiply.
Chemicals that block the activity of VCP are 10 times more powerful at stopping the virus than existing medications that target HCMV directly, the study found.
By targeting the affected cells instead of the virus, the approach could also cut the chances of the virus becoming resistant to the therapy, researchers say.
Drugs that target VCP are already being developed as potential therapies for cancer.
Studies to check whether the drugs are safe for use will be needed before they could be tested as a therapy for the virus.
The study was published in the journal PLOS Pathogens.
Go to Original
Tests on infected cells found that blocking the molecule with a chemical inhibitor stops the virus from multiplying. Dr Finn Grey, a Senior Research Fellow at the University of EdinburghÂs Roslin Institute, said: ÂBy gaining a better understanding of how the virus works, we can develop improved antiviral drugs. While more work is required, this study shows the potential of such approaches.Â
The molecule  called VCP  is a component of the infected cell rather than a substance produced by the virus itself. Researchers at the University of EdinburghÂs Roslin Institute found the virus is dependent on VCP to replicate its genetic material and multiply.
Chemicals that block the activity of VCP are 10 times more powerful at stopping the virus than existing medications that target HCMV directly, the study found.
By targeting the affected cells instead of the virus, the approach could also cut the chances of the virus becoming resistant to the therapy, researchers say.
Drugs that target VCP are already being developed as potential therapies for cancer.
Studies to check whether the drugs are safe for use will be needed before they could be tested as a therapy for the virus.
The study was published in the journal PLOS Pathogens.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries